{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:17:12Z","timestamp":1774120632316,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1378\/chest.06-3009","type":"journal-article","created":{"date-parts":[[2007,10,20]],"date-time":"2007-10-20T23:00:20Z","timestamp":1192921220000},"page":"1756-1763","source":"Crossref","is-referenced-by-count":33,"title":["The Efficacy and Safety of Combination Salmeterol (50 \u03bcg)\/Fluticasone Propionate (500 \u03bcg) Inhalation Twice Daily Via Accuhaler in Chinese Patients With COPD"],"prefix":"10.1016","volume":"132","author":[{"given":"Jin-Ping","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya Mei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong Guang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Zheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shao-Guang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tie-ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Fa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Dao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan-Shan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.06-3009_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1046\/j.1440-1843.2003.00433.x","article-title":"The impact of tobacco on lung health in China","volume":"8","author":"Zhang","year":"2003","journal-title":"Respirology"},{"key":"10.1378\/chest.06-3009_bib2","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(96)07492-2","article-title":"Alternative projections of mortality and disability by cause 1990\u20132020: Global Burden of Disease Study","volume":"349","author":"Murray","year":"1997","journal-title":"Lancet"},{"key":"10.1378\/chest.06-3009_bib3","first-page":"747","article-title":"Epidemiologic analysis of COPD in Guangdong province","volume":"85","author":"Liu","year":"2005","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1378\/chest.06-3009_bib4","author":"World Health Organization"},{"key":"10.1378\/chest.06-3009_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/thx.52.suppl_5.1","article-title":"Guidelines for the management of chronic obstructive pulmonary disease","volume":"52","author":"British Thoracic Society","year":"1997","journal-title":"Thorax"},{"key":"10.1378\/chest.06-3009_bib6","first-page":"S77","article-title":"Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma","volume":"152","author":"American Thoracic Society","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-3009_bib7","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.06-3009_bib8","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1164\/ajrccm.157.5.9709032","article-title":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease","volume":"157","author":"Seemungal","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-3009_bib9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-3009_bib10","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 \u03bcg)\/salmeterol (50 \u03bcg) combined in the discus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"key":"10.1378\/chest.06-3009_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2005.12.049","article-title":"Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases","volume":"533","author":"Sin","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1378\/chest.06-3009_bib12","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.06-3009_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1378\/chest.06-3009_bib14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1378\/chest.129.4.893","article-title":"Airway blood flow reactivity in healthy smokers and in ex-smokers with or without COPD","volume":"129","author":"Mendes","year":"2006","journal-title":"Chest"},{"key":"10.1378\/chest.06-3009_bib15","author":"Global Initiative for Chronic Obstructive Lung Disease"},{"key":"10.1378\/chest.06-3009_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.06-3009_bib17","first-page":"511","article-title":"Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals","volume":"9","author":"Xie","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.1378\/chest.06-3009_bib18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2006.09.029","article-title":"Race-ethnicity, crime, and other factors associated with adherence to inhaled corticosteroids","volume":"119","author":"Williams","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1378\/chest.06-3009_bib19","first-page":"5","article-title":"Optimal assessment and management of chronic obstructive pulmonary disease (COPD): European Respiratory Society consensus statement","volume":"16","author":"Siafakas","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"10.1378\/chest.06-3009_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Standardized lung function testing: official statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"10.1378\/chest.06-3009_bib21","first-page":"50","article-title":"Normative values for pulmonary function testing in Chinese adults","volume":"115","author":"Zheng","year":"2002","journal-title":"Chin Med J (Engl)"},{"key":"10.1378\/chest.06-3009_bib22","doi-asserted-by":"crossref","first-page":"770","DOI":"10.7326\/0003-4819-118-10-199305150-00003","article-title":"Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids: a 4-year prospective study","volume":"118","author":"Dompeling","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1378\/chest.06-3009_bib23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199211123272003","article-title":"A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease: Dutch Chronic Non-specific Lung Disease Study Group","volume":"327","author":"Kerstjens","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.06-3009_bib24","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1164\/ajrccm.156.6.9612096","volume":"156","author":"Collet","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-3009_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.06-1316","article-title":"Risk indexes for exacerbations and hospitalizations due to COPD","volume":"131","author":"Niewoehner","year":"2007","journal-title":"Chest"},{"key":"10.1378\/chest.06-3009_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/rccm.200508-1321OC","article-title":"Antiinflammatory effects of salmeterol\/fluticasone propionate in chronic obstructive lung disease","volume":"173","author":"Barnes","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.06-3009_bib27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2006.00897.x","article-title":"Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year","volume":"11","author":"Zhou","year":"2006","journal-title":"Respirology"},{"key":"10.1378\/chest.06-3009_bib28","series-title":"Asthma","first-page":"1869","article-title":"Management of asthma in developing counties","author":"Zhong","year":"1997"},{"key":"10.1378\/chest.06-3009_bib29","first-page":"740","article-title":"Systemic side effects of long-term treatment with low dose inhaled corticosteroids in children with asthma","volume":"24","author":"Chen","year":"2001","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215524446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215524446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,3]],"date-time":"2019-01-03T11:56:28Z","timestamp":1546516588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215524446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0012369215524446"],"URL":"https:\/\/doi.org\/10.1378\/chest.06-3009","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}